News for Healthier Living

AACR: Topical gel relieves painful skin rash side effect caused by targeted therapy for colorectal cancer

(mid dot) LUT014, a topical BRAF inhibitor made by Lutris Pharma, is the first agent to treat the cause of the rash without interfering with the treatment itself (mid dot) Over two-thirds of patients had successful treatment with the higher dose of LUT014 compared to one-third with placebo

April 27, 2025


May 9 2025

May 8 2025

May 7 2025

May 6 2025

May 5 2025

May 2 2025

May 1 2025

April 30 2025

April 29 2025

April 28 2025

April 27 2025

April 26 2025

April 25 2025